> Research summary—not medical advice. This page synthesizes published research on a mechanism-level intervention. It is not a clinical recommendation.
Consult a qualified healthcare provider before making any changes to diet, supplementation, or treatment.
Evidence map2 cited passagesInspect provenance +
| Strain | Condition | Evidence Level | Key Findings | |--------|-----------|---------------|--------------| | B. longum subsp. longum 35624 (historically “B. infantis 35624”) | ibs | Historical-label RCTs | Reported strain-specific outcomes cannot be generalized to B. longum subsp. infantis | | L. rhamnosus GG (LGG) | ibs-D, antibiotic-associated diarrhea |
Strains that only survive transit without immune engagement, or that modulate immunity without ecological persistence, show weaker clinical effects. Historical studies of strain 35624 used an infantis label, but comparative genomics assigns that strain to B. longum subsp. longum; its findings must remain strain-specific.
Contents
1. Overview2. Strain-Specific Evidence Table3. The Dual Functionality Requirement4. Metal Sponge Caveat5. Dosage and Administration6. Contraindications and Risks7. ConnectionsOverview#
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. The critical principle in probiotic medicine is strain specificity—benefits demonstrated for one strain do NOT transfer to other strains, even within the same species.
Lactobacillus rhamnosus GG and Lactobacillus rhamnosus ATCC 7469 are as different therapeutically as aspirin and acetaminophen.
> Clinical disclaimer: Probiotic selection must be strain-specific and condition-matched. "Take a probiotic" is not a medical recommendation. Immunocompromised patients (transplant, chemotherapy, advanced HIV) face risk of bacteremia/fungemia from live organisms.
Probiotic quality varies enormously between manufacturers; third-party-verified products are preferred. All probiotic decisions should involve clinical supervision.
Strain-Specific Evidence Table#
| Strain | Condition | Evidence Level | Key Findings |
|---|---|---|---|
| B. longum subsp. longum 35624 (historically “B. infantis 35624”) | Irritable Bowel Syndrome (IBS) | Historical-label RCTs | Reported strain-specific outcomes cannot be generalized to B. longum subsp. infantis[1]Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624Friedrich Altmann, Paul Kosma, Amy O'Callaghan et al. · 2016Open reference 1 ↓ |
| L. rhamnosus GG (LGG) | Irritable Bowel Syndrome (IBS)-D, antibiotic-associated diarrhea | RCT (validated) | Reduces IBS-D symptoms; prevents AAD in children and adults |
| E. coli Nissle 1917 | Ulcerative Colitis | RCT (validated) | Maintains remission; efficacy equivalent to mesalazine |
| VSL#3 (8-strain) | Ulcerative Colitis, pouchitis | RCT (validated) | Maintains remission; prevents pouchitis recurrence |
| L. helveticus R0052 + B. longum R0175 | Depression | RCT (promising) | Reduces depression/anxiety scores; lowers cortisol |
| L. plantarum PS128 | Autism Spectrum Disorder | RCT (promising) | Improves opposition/defiance behaviors; modulates dopamine |
| Multi-strain (various) | Multiple Sclerosis | RCT (promising) | Improves EDSS; reduces CRP and IL-6; modulates PBMC gene expression |
| L. reuteri DSM 17938 | Infant colic, functional GI | RCT (validated) | Reduces crying time; well-studied safety in infants |
| S. boulardii CNCM I-745 | C. difficile recurrence | RCT (validated) | Reduces CDI recurrence as adjunct to antibiotics |
| B. coagulans GBI-30, 6086 | Irritable Bowel Syndrome (IBS), abdominal pain | RCT (promising) | Reduces abdominal pain and bloating |
The Dual Functionality Requirement#
Effective probiotic strains must satisfy two functional requirements simultaneously:
- Ecological function: The strain must survive transit, engraft (even transiently), and modify the gut ecosystem—competing with pathobionts for niche space, producing SCFAs, strengthening the barrier, or producing antimicrobial compounds.
- Immunological function: The strain must interact with the mucosal immune system to modulate the Th1/Th2/Th17/Treg balance, reduce inflammatory cytokines, or activate tolerogenic pathways (e.g., AhR ligand production, butyrate-mediated HDAC inhibition).
Strains that only survive transit without immune engagement, or that modulate immunity without ecological persistence, show weaker clinical effects. Historical studies of strain 35624 used an infantis label, but comparative genomics assigns that strain to B. longum subsp. longum; its findings must remain strain-specific.[1]Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624Friedrich Altmann, Paul Kosma, Amy O'Callaghan et al. · 2016Open reference 1 ↓
Metal Sponge Caveat#
Many probiotic organisms bind and sequester heavy metals in the gut lumen—a property sometimes marketed as "detoxification." This has important implications.
Benefit: Lactobacillus and Bifidobacterium strains can bind Lead, Cadmium, Mercury, and Arsenic, reducing intestinal absorption (demonstrated in animal models and limited human trials). Risk: Metal-binding probiotics may also sequester essential metals (Zinc, Iron, Selenium), potentially worsening nutritional deficiencies in already-depleted patients.
Clinical implication: When using probiotics in patients with both toxic metal exposure AND essential metal deficiency, separate probiotic dosing from essential metal supplementation by 2+ hours.
Research gap: No RCTs have systematically evaluated the impact of probiotic metal sequestration on essential mineral status in deficient populations.
Dosage and Administration#
CFU range: Most evidence supports 1-50 billion CFU/day, strain-dependent. Timing: Generally with or shortly before meals (bile acid exposure varies by strain). Duration: Minimum 4-8 weeks for clinical assessment; effects often wane after discontinuation.
Form: Refrigerated capsules or sachets generally preferred; some spore-forming strains (B. coagulans) are shelf-stable. Quality: Third-party verification (USP, NSF, ConsumerLab) recommended; label claims frequently inaccurate.
Contraindications and Risks#
Immunocompromised patients: Risk of bacteremia (Lactobacillus), fungemia (Saccharomyces), or endocarditis; probiotics should be used with extreme caution or avoided. Short bowel syndrome: Increased risk of D-lactic acidosis from Lactobacillus overgrowth. Central venous catheters: Saccharomyces boulardii can contaminate lines and cause fungemia.
Critically ill patients: PROPATRIA trial showed increased mortality with probiotics in severe acute pancreatitis. SIBO: Some patients with small intestinal bacterial overgrowth may worsen with additional live organisms.
Connections#
Entities: Lactobacillus, Bifidobacterium, Streptococcus thermophilus, Faecalibacterium prausnitzii, Escherichia coli
Concepts: Dysbiosis, Gut Microbiome, Immune Balance, Gut-Brain Axis, Short-Chain Fatty Acids (SCFAs), Indoles
Related interventions: E. coli Nissle 1917 (specific strain page), probiotics asd dysbiosis (ASD-specific), Fecal Microbiota Transplantation (FMT) (related live biotherapeutic), Vitamin D Supplementation (synergistic in PCOS), Prebiotics (synergistic with probiotics as synbiotics)
Signatures: Ulcerative Colitis, Irritable Bowel Syndrome (IBS), Multiple Sclerosis, Depression, Autism Spectrum Disorder
> Educational content, not medical advice. This page describes mechanisms by which the intervention interacts with the microbiome and metal ecology. It is not a treatment recommendation.
Clinical decisions about any intervention should be made with a qualified healthcare practitioner who knows your individual history.
References 1
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Friedrich Altmann, Paul Kosma, Amy O'Callaghan et al. (2016). Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624. PLOS ONE.
Article network
Mentioned here 18
Pages linking here 8
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Canonicalize Bifidobacterium infantis
Karen Pendergrass · +8 −7
Inspect exact Git diff ↗ - published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +24 −24
Inspect exact Git diff ↗ - published revision
pre-overnight checkpoint 2026-04-18
WikiBiome Deploy Bot · +2 −0
Inspect exact Git diff ↗ - published revision
Adversarial audit fixes: confidence downgrades, disclaimers, STOP safety, entity cleanup
WikiBiome Deploy Bot · +8 −1
Inspect exact Git diff ↗ - published revision
WikiBiome v2 migration: signature pages + safety fixes + gap analysis
WikiBiome Deploy Bot · +128 −0
Inspect exact Git diff ↗